Gilead Sciences Statistics

Total Valuation

Gilead Sciences has a market cap or net worth of ARS 225.88 trillion. The enterprise value is 244.00 trillion.

Market Cap	225.88T
Enterprise Value	244.00T

Important Dates

The next confirmed earnings date is Thursday, May 7, 2026.

Earnings Date	May 7, 2026
Ex-Dividend Date	Mar 13, 2026

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	n/a
Shares Change (QoQ)	-0.08%
Owned by Insiders (%)	0.10%
Owned by Institutions (%)	88.87%
Float	1.24B

Valuation Ratios

The trailing PE ratio is 18.29 and the forward PE ratio is 15.10.

PE Ratio	18.29
Forward PE	15.10
PS Ratio	5.29
PB Ratio	6.88
P/TBV Ratio	n/a
P/FCF Ratio	16.46
P/OCF Ratio	15.53
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 11.75, with an EV/FCF ratio of 17.78.

EV / Earnings	19.76
EV / Sales	5.89
EV / EBITDA	11.75
EV / EBIT	14.66
EV / FCF	17.78

Financial Position

The company has a current ratio of 1.55, with a Debt / Equity ratio of 1.13.

Current Ratio	1.55
Quick Ratio	1.23
Debt / Equity	1.13
Debt / EBITDA	1.73
Debt / FCF	2.70
Interest Coverage	11.54

Financial Efficiency

Return on equity (ROE) is 40.66% and return on invested capital (ROIC) is 26.86%.

Return on Equity (ROE)	40.66%
Return on Assets (ROA)	12.52%
Return on Invested Capital (ROIC)	26.86%
Return on Capital Employed (ROCE)	25.03%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	2.51B
Profits Per Employee	726.55M
Employee Count	17,000
Asset Turnover	0.50
Inventory Turnover	3.58

Taxes

In the past 12 months, Gilead Sciences has paid 1.87 trillion in taxes.

Income Tax	1.87T
Effective Tax Rate	13.13%

Stock Price Statistics

The stock price has increased by +23.64% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+23.64%
50-Day Moving Average	36.72
200-Day Moving Average	30.66
Relative Strength Index (RSI)	39.80
Average Volume (20 Days)	77

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	3.45

Income Statement

In the last 12 months, Gilead Sciences had revenue of ARS 42.73 trillion and earned 12.35 trillion in profits. Earnings per share was 9,840.49.

Revenue	42.73T
Gross Profit	33.69T
Operating Income	17.15T
Pretax Income	14.22T
Net Income	12.35T
EBITDA	21.16T
EBIT	17.15T
Earnings Per Share (EPS)	9,840.49

Balance Sheet

The company has 13.95 trillion in cash and 37.07 trillion in debt, giving a net cash position of -18,801.44 billion.

Cash & Cash Equivalents	13.95T
Total Debt	37.07T
Net Cash	-18,801.44B
Net Cash Per Share	n/a
Equity (Book Value)	32.83T
Book Value Per Share	26,550.91
Working Capital	9.48T

Cash Flow

In the last 12 months, operating cash flow was 14.54 trillion and capital expenditures -817.14 billion, giving a free cash flow of 13.72 trillion.

Operating Cash Flow	14.54T
Capital Expenditures	-817.14B
Depreciation & Amortization	3.88T
Net Borrowing	-2,511.76B
Free Cash Flow	13.72T
FCF Per Share	n/a

Margins

Gross margin is 78.84%, with operating and profit margins of 40.14% and 28.90%.

Gross Margin	78.84%
Operating Margin	40.14%
Pretax Margin	33.27%
Profit Margin	28.90%
EBITDA Margin	49.51%
EBIT Margin	40.14%
FCF Margin	32.12%

Dividends & Yields

This stock pays an annual dividend of 692.11, which amounts to a dividend yield of 2,038.00%.

Dividend Per Share	692.11
Dividend Yield	2,038.00%
Dividend Growth (YoY)	43.11%
Years of Dividend Growth	5
Payout Ratio	7.03%
Buyback Yield	0.24%
Shareholder Yield	2,058.24%
Earnings Yield	5.47%
FCF Yield	6.08%

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Gilead Sciences has an Altman Z-Score of 3.9 and a Piotroski F-Score of 7.

Altman Z-Score	3.9
Piotroski F-Score	7